OR WAIT null SECS
BioPharm International speaks to the United States Pharmacopeial Convention to find out who will truly have the final say when it comes to biosimilar nomenclature.
There is still some uncertainty surrounding whether a biosimilar will share the same compendial identity-or biological product monograph-as its reference product. It has been reported that FDA determined that the the United States Pharmacopeial Convention’s (USP’s) monograph for filgrastim does not apply to the first-ever approved biosimilar product, Zarxio (filgrastim-sndz). In this BioPharm International article, Randi Hernandez speaks to USP to find out more about how the naming process for a drug occurs and who truly will have the final say when it comes to biosimilar nomenclature.